Bulletin
Investor Alert

Cabaletta Bio Inc.

NAS: CABA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 25, 2022, 3:48 p.m.

/zigman2/quotes/214676209/composite

$

3.60

Change

+0.12 +3.45%

Volume

Volume 410

Quotes are delayed by 20 min

/zigman2/quotes/214676209/composite

Previous close

$ 3.53

$ 3.48

Change

-0.05 -1.42%

Day low

Day high

$3.32

$3.55

Open

52 week low

52 week high

$0.59

$13.24

Open

Company Description

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells ...

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Valuation

Price to Book Ratio

0.93

Enterprise Value to EBITDA

0.43

Efficiency

Liquidity

Current Ratio

14.86

Quick Ratio

14.86

Cash Ratio

14.59

Profitability

Return on Assets

-38.40

Return on Equity

-40.69

Return on Total Capital

-40.71

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Steven Nichtberger 59 2017 Chairman, President & Chief Executive Officer
Mr. Anup Marda 41 2019 CFO & Principal Accounting Officer
Dr. Gwendolyn Binder-Scholl 45 2019 Executive Vice President-Science & Technology
Dr. David J. Chang 56 2019 Chief Medical Officer
Dr. Samik Basu - 2019 VP-Preclinical Research & Translational Medicine

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/19/2022 Steven Nichtberger
President & CEO; Director
8,127   Acquisition at $1.25 per share. 10,158
10/18/2022 Steven Nichtberger
President & CEO; Director
141,873   Acquisition at $0.99 per share. 140,454
10/18/2022 Mark Simon
Director
7,000   Acquisition at $0.98 per share. 6,860
10/18/2022 Mark Simon
Director
118,000   Acquisition at $0.98 per share. 115,640
10/18/2022 Anup Marda
Chief Financial Officer
50,000   Acquisition at $0.99 per share. 49,500
10/18/2022 Gwendolyn Binder-Scholl
See Remarks
20,000   Acquisition at $0.99 per share. 19,800
10/18/2022 Catherine Bollard
Director
1,000   Acquisition at $0.99 per share. 990
01/31/2022 Steven Nichtberger
President & CEO; Director
50,000   Derivative/Non-derivative trans. at $1.01 per share. 50,500
11/01/2021 5AM Venture Management LLC
36,544   Disposition at $13 per share. 475,072
11/01/2021 5AM Venture Management LLC
258,456   Disposition at $13 per share. 3,359,928
09/07/2021 5AM Venture Management LLC
625,000   Disposition at $9.7 per share. 6,062,500
01/12/2021 5AM Venture Management LLC
10,530   Disposition at $13 per share. 136,890
01/12/2021 5AM Venture Management LLC
74,470   Disposition at $13 per share. 968,110
01/08/2021 5AM Venture Management LLC
37,411   Disposition at $13 per share. 486,343
01/08/2021 5AM Venture Management LLC
264,589   Disposition at $13 per share. 3,439,657
12/10/2020 5AM Venture Management LLC
36,916   Disposition at $14.75 per share. 544,511
12/10/2020 5AM Venture Management LLC
261,084   Disposition at $14.75 per share. 3,850,989
10/29/2019 5AM Venture Management LLC
454,545   Acquisition at $11 per share. 4,999,995
10/29/2019 Deerfield Management Co. LP
700,000   Acquisition at $11 per share. 7,700,000
10/29/2019 5AM Venture Management LLC
3,214,721   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Deerfield Management Co. LP
464,253   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Deerfield Management Co. LP
464,253   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Steven Nichtberger
President & CEO; Director
60,483   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Redmile Group LLC
696,378   Derivative/Non-derivative trans. at $0 per share. 0
10/29/2019 Mark Simon
Director
18,144   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/caba

MarketWatch News on CABA

  1. Cabaletta Bio stock price target cut to $10 from $20 at Mizuho

    5:57 a.m. May 25, 2022

    - Tomi Kilgore

  2. Cabaletta Bio initiated at buy with $21 price target at Chardan Research

    8:20 a.m. Jan. 8, 2021

    - Tonya Garcia

  3. Cabaletta Bio started at outperform with $25 stock price target at Evercore ISI

    7:40 a.m. Nov. 19, 2019

    - Tomi Kilgore

  4. Cabaletta Bio shares slide 17.6% in trading debut

    11:28 a.m. Oct. 25, 2019

    - Ciara Linnane

/news/nonmarketwatch/company/us/caba

Other News on CABA

  1. MMAT, PRCH and CABA among mid-day movers

    12:51 p.m. Nov. 14, 2022

    - Seeking Alpha

  2. Cabaletta Bio GAAP EPS of -$0.39 beats by $0.09

    9:00 a.m. Nov. 10, 2022

    - Seeking Alpha

  3. 10-Q: CABALETTA BIO, INC.

    7:44 a.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. 5 Stocks Insiders Are Buying in October

    3:56 p.m. Oct. 20, 2022

    - GuruFocus.com

  5. ASTI, CABA and PEGY among mid-day movers

    12:04 p.m. Oct. 20, 2022

    - Seeking Alpha

  6. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    5:04 p.m. Sept. 16, 2022

    - Seeking Alpha

  7. NBEV, APRN and RMTI among mid-day movers

    11:55 a.m. Aug. 30, 2022

    - Seeking Alpha

  8. DRUG, CABA and ALLR among mid-day movers

    11:46 a.m. Aug. 22, 2022

    - Seeking Alpha

  9. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    1:01 p.m. Aug. 11, 2022

    - Seeking Alpha

  10. 10-Q: CABALETTA BIO, INC.

    6:44 a.m. Aug. 11, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  11. What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

    11:00 a.m. June 9, 2022

    - Zacks.com

  12. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    11:24 a.m. May 27, 2022

    - Seeking Alpha

  13. Cabaletta Bio updates Phase 1 interim data for lead asset

    11:18 a.m. May 18, 2022

    - Seeking Alpha

  14. EDRY, WKEY and HPK among mid-day movers

    11:55 a.m. April 25, 2022

    - Seeking Alpha

  15. Cabaletta Bio (CABA) Investor Presentation - Slideshow

    11:13 a.m. April 14, 2022

    - Seeking Alpha

  16. 10-K: CABALETTA BIO, INC.

    7:28 a.m. March 17, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  17. Loading more headlines...

At a Glance

Cabaletta Bio, Inc.

2929 Arch Street

Suite 600

Philadelphia, Pennsylvania 19104

Phone

1 2677593100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-46.29M

Employees

54.00

/news/pressrelease/company/us/caba

Press Releases on CABA

  1. Wednesday 10/19 Insider Buying Report: CABA, OMI

    9:32 a.m. Oct. 19, 2022

    - MarketNewsVideo.com

  2. 4 Hot Penny Stocks To Watch This Week

    2:32 p.m. Aug. 22, 2022

    - Penny Stocks

  3. Loading more headlines...
Link to MarketWatch's Slice.